Clinical trials: Movement Disorder
- Condition Movement Disorder
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Angelman Syndrome
A Study in Adults and Adolescents With Angelman Syndrome (STARS)
The purpose of the study is to assess the safety and tolerability of oral OV101 (gaboxadol) in adult and adolescent subjects with Angelman syndrome. In addition, several exploratory efficacy outcome measures will be investigated.
- Trial name
- NCT02996305
- Testing
- OV101 Regimen 1, OV101 regimen 2
- Where
- 13 sites in United States, Israel
- Volunteers
- 88 people
- Sponsor
- Healx AI
Hepatolenticular Degeneration; Wilson
Performance and Safety of MEX-CD1 Low-volume Continuous Veno-venous Haemodialysis Medical Device for Copper-extraction in Patients With Wilson's Disease
The goal of this clinical trial is to test the MEX-CD1 hemodialysis medical device in patients suffering from Wilson's Disease. The main questions it aims to answer are: Does the device work as expected by removing the excess of…
- Trial name
- MEXWILS (NCT05917327)
- Testing
- Low-volume continuous veno-venous haemodialysis
- Where
- 4 sites in France, Spain
- Volunteers
- 1 people
- Sponsor
- Mexbrain
Multiple System Atrophy
Long-term Follow-up of Phase 1 Clinical Trial of CS10BR05(CS10BR05-MSA101)
The study purpose is conducting follow-up surveillance for the incidence of adverse events and efficacy of subjects participated in phase 1 trial to evaluate the safety and tolerability of autologous bone marrow-derived…
- Trial name
- NCT04495582
- Where
- South Korea
- Volunteers
- 8 people
- Sponsor
- Corestemchemon, Inc.
Wilson Disease
Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
The study will evaluate the efficacy and safety of ALXN1840 (formerly called WTX101) administered for 48 weeks compared to standard of care (SoC) in Wilson Disease (WD) participants aged 12 and older in the Primary Evaluation…
- Trial name
- NCT03403205
- Testing
- ALXN1840, SoC Therapy
- Where
- 56 sites in United States, Australia and 20 more
- Volunteers
- 214 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Parkinson's Disease (PD)
Coordinated Reset Deep Brain Stimulation
The study will explore the viability of an alternative/novel programming strategy in Deep Brain Stimulation (DBS) for patients with Parkinson's Disease (PD).
- Trial name
- RESET-DBS (NCT03732898)
- Testing
- Novel Programming (nDBS), Conventional Programming (cDBS)
- Where
- 2 sites in Germany
- Volunteers
- 15 people
- Sponsor
- Boston Scientific Corporation
Parkinson's Disease, Malignant Melanoma
A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma
Patients with Parkinson's disease will be seen by a dermatologist who will biopsy any suspicious skin lesions.
- Trial name
- NCT00203008
- Volunteers
- 2,106 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Autism Spectrum Disorder
An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder
The investigators hypothesize that EPI-743 may provide clinical benefit to children with Autism Spectrum Disorder.
- Trial name
- Autism (NCT02226458)
- Testing
- EPI-743
- Sponsor
- Edison Pharmaceuticals Inc
Dyskinesia, Cerebral Palsy
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
The primary objective of this study is to evaluate the efficacy of valbenazine versus placebo on improving chorea in pediatric and adult participants who have dyskinesia due to cerebral palsy (DCP) with choreiform movements.
- Trial name
- NCT05206513
- Testing
- Valbenazine
- Where
- 38 sites in United States, Argentina and 8 more
- Volunteers
- 86 people
- Sponsor
- Neurocrine Biosciences
Spinal Cord Stimulation, Deep Brain Stimulation
Implantable Systems Performance Registry
The Implantable Systems Performance Registry (ISPR) was developed to evaluate the long-term reliability and performance of market-released Medtronic Neuromodulation infusion and stimulation products.
- Conditions
- Spinal Cord Stimulation, Deep Brain Stimulation, Drug Infusion (Implantable Pumps), Sacral Neuromodulation
- Trial name
- ISPR (NCT00959296)
- Testing
- Various
- Where
- 50 sites in United States, Austria and 5 more
- Volunteers
- 10,981 people
- Sponsor
- MedtronicNeuro
Cerebral Palsy
Development of a Robotic Ankle Assist Device
The overall objectives of this work is to establish feasibility of a robotic ankle assist device (RAAD) to improve mobility in free-living settings and to establish the RAAD as an effective tool to provide increased dose and…
- Trial name
- NCT04516343
- Testing
- Robotic Ankle Assist Device (RAAD)
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- BiOMOTUM, Inc.
Essential Tremor, Parkinson's Disease
Global Registry: ExAblate Neuro MR Guided Focused Ultrasound (MRgFUS) of Neurological Disorders:
A global post approval study to collect safety and effectiveness data related to ExAblate Neuro for the treatment of certain disorders such as Essential Tremor, Parkinson's Movement Disorders, or Neuropathic Pain within the…
- Conditions
- Essential Tremor, Parkinson's Disease, Movement Disorders, Neuropathic Pain
- Trial name
- NCT03100474
- Where
- 9 sites in United States, Canada and 2 more
- Volunteers
- 500 people
- Sponsor
- InSightec
Huntington Disease
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
WVE-HDSNP2-002 is an open-label extension (OLE) study to evaluate the safety, tolerability, PK, PD, and clinical effects of WVE-120102 in adult patients with early manifest HD who carry a targeted single nucleotide polymorphism…
- Trial name
- NCT04617860
- Testing
- WVE-120102
- Where
- 20 sites in Australia, Canada and 5 more
- Volunteers
- 36 people
- Sponsor
- Wave Life Sciences USA, Inc.
Huntington Disease
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease
WVE-HDSNP1-002 is an open-label extension (OLE) study to evaluate the safety, tolerability, PK, PD, and clinical effects of WVE-120101 in adult patients with early manifest HD who carry a targeted single nucleotide polymorphism…
- Trial name
- NCT04617847
- Testing
- WVE-120101
- Where
- 18 sites in Australia, Canada and 5 more
- Volunteers
- 27 people
- Sponsor
- Wave Life Sciences USA, Inc.
Parkinson Disease
Kinetic Tremor in Parkinsons Disease: Its Course Under Pramipexole (Mirapexin®) Treatment and Impact on Quality of Life
The study will compare the effect of pramipexole on different types of tremor and particularly kinetic tremor in early and advanced Parkinson's disease patients and will evaluate the course of tremor measured with spiralometry…
- Trial name
- NCT01100073
- Where
- 215 sites in Estonia, Latvia and 6 more
- Volunteers
- 1,703 people
- Sponsor
- Boehringer Ingelheim
Epilepsy, Generalized, Absence Epilepsy
Detecting Absence Seizures Using Eye Tracking
The goal of this study is to develop a comfortable system that uses a wearable eye-tracker similar to eyeglasses to assist people with epilepsy in counting and measuring the severity of seizures.
- Conditions
- Epilepsy, Generalized, Absence Epilepsy, Absence Seizures, Seizures
- Trial name
- NCT04439656
- Testing
- Eye movement analysis
- Where
- 5 sites in United States
- Volunteers
- 150 people
- Sponsor
- Rachel Kuperman
Angelman Syndrome
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome
A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Angelman syndrome
- Trial name
- AS-001 (NCT05011851)
- Testing
- NNZ-2591
- Where
- 3 sites in Australia
- Volunteers
- 17 people
- Sponsor
- Neuren Pharmaceuticals Limited
Parkinson Disease
Development of Digital Diagnostic Devices for Parkinson's Disease
In this project, ocular motor, pupil and gait data in people with Parkinson's disease (PD) will be collected in order to develop machine learning models for the diagnosis and monitoring of PD.
- Trial name
- NCT06663826
- Testing
- oculomotor and pupillary function assessment
- Where
- Switzerland
- Volunteers
- 116 people
- Sponsor
- machineMD AG
Angelman Syndrome
A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.
This is a two-part, Phase IIa, multicenter, 12-week, open-label study. Up to 56 participants with deletion AS aged 5-17 years (inclusive) will be enrolled in the study.
- Trial name
- Aldebaran (NCT05630066)
- Testing
- Alogabat
- Where
- 19 sites in United States, Australia and 4 more
- Volunteers
- 48 people
- Sponsor
- Hoffmann-La Roche
Parkinson's Disease
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
Eligible participants, who participated in the ADAGIO trial and who sign an approved informed consent form, will be enrolled into the study at their original study locations.
- Trial name
- NCT00936676
- Testing
- rasagiline mesylate
- Where
- 102 sites in United States, Argentina and 11 more
- Volunteers
- 684 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Scoliosis; Adolescence
O-arm Assessment of Vertebral Movement Using ST2R Technique
The study is quantifying how the patients' back has been corrected using Medicrea's hardware through imaging taken before,during and after the surgery.
- Trial name
- NCT03609138
- Testing
- Spinal Hardware
- Sponsor
- Medicrea, USA Corp.